THE EXPERIENCE OF THE USE OF ALLOKINE-ALPHA IN TREATMENT OF CHRONIC PERSISTING VIRAL MIXT-INFECTIONS IN MEN

Юрий Заседа, Руслан Соломенный, Фарид Шихалиев
{"title":"THE EXPERIENCE OF THE USE OF ALLOKINE-ALPHA IN TREATMENT OF CHRONIC PERSISTING VIRAL MIXT-INFECTIONS IN MEN","authors":"Юрий Заседа, Руслан Соломенный, Фарид Шихалиев","doi":"10.37321/ujmh.2019.01-02","DOIUrl":null,"url":null,"abstract":"Relevance. Chronic persistent viral infections are a category of andro-urological problems that currently have no defi nite solutions.The aim of the study is to evaluate the eff ectiveness of treatment of chronic infl ammatory diseasesof the prostate gland (persistent viral mixed infections: combinations of herpes simplex virus (first and second types) and human papilloma virus using the drug “Allokin-alpha”(Alloferonum)), in comparison with recombinant human interferon-2b.Materials and methods. The study was conducted on a contingent of 60 patients of the clinic “Men’s Health”, Kyiv. The study design suggested the use of 2 parallel groups of 30 patients receiving treatment according to diff erent therapeutic models.The results of the study. When comparing therapeutic models using parenteral administration of Alloferonum in the composition of the drug “Allokin-alpha” and parenteral administration of recombinant human interferon-2b in parallel groups of patients suff ering from chronic persistent mixed infections, a number of diff erences regarding serological and clinical effi cacy and long-term eff ects were found.Findings. The eff ectiveness of the elimination of chronic persistent viral mixed infections for Alloferonum was 66,7%, for recombinant human interferon-2b in - 40%. The catamnestic eff ects of therapeutic models also diff ered. For Alloferonum 6 months after the course of treatment, the recovery of serological activity of viruses occurred in 13,4% of patients, the return of systemic clinical manifestations was observed in 23,3% of patients, the return of symptoms of specifi c prostatitis - in 10,0% of patients. For recombinant human interferon-2b, similar fi gures were 23,0%, 33,3% and 20,0%, respectively.","PeriodicalId":204320,"journal":{"name":"Men’s Health, Gender and Psychosomatic Medicine","volume":"35 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Men’s Health, Gender and Psychosomatic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37321/ujmh.2019.01-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Relevance. Chronic persistent viral infections are a category of andro-urological problems that currently have no defi nite solutions.The aim of the study is to evaluate the eff ectiveness of treatment of chronic infl ammatory diseasesof the prostate gland (persistent viral mixed infections: combinations of herpes simplex virus (first and second types) and human papilloma virus using the drug “Allokin-alpha”(Alloferonum)), in comparison with recombinant human interferon-2b.Materials and methods. The study was conducted on a contingent of 60 patients of the clinic “Men’s Health”, Kyiv. The study design suggested the use of 2 parallel groups of 30 patients receiving treatment according to diff erent therapeutic models.The results of the study. When comparing therapeutic models using parenteral administration of Alloferonum in the composition of the drug “Allokin-alpha” and parenteral administration of recombinant human interferon-2b in parallel groups of patients suff ering from chronic persistent mixed infections, a number of diff erences regarding serological and clinical effi cacy and long-term eff ects were found.Findings. The eff ectiveness of the elimination of chronic persistent viral mixed infections for Alloferonum was 66,7%, for recombinant human interferon-2b in - 40%. The catamnestic eff ects of therapeutic models also diff ered. For Alloferonum 6 months after the course of treatment, the recovery of serological activity of viruses occurred in 13,4% of patients, the return of systemic clinical manifestations was observed in 23,3% of patients, the return of symptoms of specifi c prostatitis - in 10,0% of patients. For recombinant human interferon-2b, similar fi gures were 23,0%, 33,3% and 20,0%, respectively.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
异丙烯- α治疗男性慢性持续性病毒混合感染的经验
的相关性。慢性持续性病毒感染是一类目前没有明确解决方案的男性泌尿系统问题。该研究的目的是评估前列腺慢性炎性疾病(持续性病毒混合感染:单纯疱疹病毒(第一和第二型)和人乳头瘤病毒的组合)的治疗效果,并与重组人干扰素2b进行比较。材料和方法。这项研究是对基辅“男子健康”诊所的60名病人进行的。研究设计建议采用2个平行组,每组30例患者根据不同的治疗模式接受治疗。研究的结果。在慢性持续性混合感染患者的平行组中,通过比较经肠外给药Alloferonum组成的药物“alloin - α”的治疗模型和经肠外给药重组人干扰素2b的治疗模型,我们发现在血清学、临床疗效和长期影响方面存在许多差异。异铁黄菌对慢性持续性病毒混合感染的根除率为66.7%,重组人干扰素2b的根除率为- 40%。不同治疗模式的治疗效果也不同。异异铁酸钠治疗6个月后,13.4%的患者血清病毒活性恢复,23.3%的患者出现全身临床症状,10.0%的患者出现特异性前列腺炎症状。对于重组人干扰素2b,类似的数字分别为23.0%、33.3%和20.0%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
НОВІТНІ МЕТОДИ ЛІКУВАННЯ ПОСТКОВІДНОГО ГІПОГОНАДИЗМУ ЯКІСНИЙ ВПЛИВ ІМУНОТЕРАПІЇ АЛЬФА/БЕТА ДЕФЕНЗИНАМИ НА РОЗВИТОК ХІМІО/ПРОМЕНЕВИХ УСКЛАДНЕНЬ ХВОРИХ НА РАК РОТОВОЇ ПОРОЖНИНИ І РОТОГЛОТКИ ОСОБЛИВОСТІ ЗМІН БІОХІМІЧНИХ ПОКАЗНИКІВ У ХВОРИХ З ІНТРАЦЕРЕБРАЛЬНО УСКЛАДНЕНИМ МОЗКОВИМ ІШЕМІЧНИМ ІНСУЛЬТОМ ПІДХОДИ ДО ОЦІНКИ ПРОВОКАТИВНОЇ ПОВЕДІНКИ ТА «ПОШУКУ УВАГИ» У КОНТЕКСТІ ІНТЕРНЕТ-ЗАЛЕЖНОСТІ ВИКОРИСТАННЯ ЕКЗОСОМ ОТРИМАНИХ З МЕЗЕНХІМАЛЬНИХ СТОВБУРОВИХ КЛІТИН У ЛІКУВАННІ ВЕНООКЛЮЗИВНОЇ ЕРЕКТИЛЬНОЇ ДИСФУНКЦІЇ
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1